---
schema_version: "secwatch.filing_event.v1"
accession: "0001808665-26-000010"
form_type: "8-K"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:53:52.195242+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assertio reports Q4 adjusted EBITDA loss of $4.1M; Rolvedon sales drop to $0.4M from $15.4M

## Summary
- Rolvedon Q4 net sales $0.4M vs $15.4M YoY; sell-in in Q3 2025 covered two quarters of demand, sales under new label expected Q2 2026.
- Sympazan net sales grew to $3.1M from $2.5M; Indocin flat at $5.5M.
- Gross margin improved to 75% from 61% on product mix and inventory write-downs in prior year.
- Adjusted EBITDA loss $4.1M vs income $3.4M last year; cash dropped to $63.4M from $93.4M in Q3.
- FY2026 guidance: net product sales $110M-$125M, Adj EBITDA $28M-$40M; CEO prioritizes Rolvedon and disciplined oncology build.

## SEC filing metadata
- accession: 0001808665-26-000010
- form_type: 8-K
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/0001808665-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/asrt-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808665-26-000010
- JSON: https://secwatch.observer/filing/0001808665-26-000010.json
- Plain text: https://secwatch.observer/filing/0001808665-26-000010.txt

## Key facts
- Earnings Releases
  Assertio Holdings, Inc. reported financial results for the fourth quarter ended December 31, 2025.
  - Period: the fourth quarter ended December 31, 2025
  - Result: reported results
  source text: today reported financial results for the fourth quarter and full year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/0001808665-26-000010-index.htm
- Earnings Releases
  Assertio Holdings, Inc. updated its the fiscal year ended December 31, 2025 guidance (initiated).
  - Period: the fiscal year ended December 31, 2025
  - Guidance: initiated
  - Result: reported results
  source text: Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/0001808665-26-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.